GSK completes $2 billion acquisition of efimosfermin from Boston Pharmaceuticals: London, UK Wednesday, July 9, 2025, 09:00 Hrs [IST] GSK plc announced the completion of its previ ...

"GSK acquires efimosfermin alfa from Boston Pharma for $2bn" was originally created and published by Pharmaceutical ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to ...

Four co-authors are employees of Boston Pharmaceuticals, and one now consults for Boston Pharmaceuticals after being employed there during this study. One other co-author reported various industry ...

Rhythm Pharmaceuticals, Inc. may be ripe in a year. At that time, setmelanotide should be approved for HO in the U.S. and ...

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

The Boston Arts Academy Foundation closed its Building Our Future fundraising campaign, surpassing its $35 million goal, ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston Pharmaceuticals, pledging another $800 million in milestone payments if the ...

A Cambridge biotech company is preparing to lay off its entire staff of more than 300 after being acquired by another firm.

Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks -- -- Post-hoc analysis showed BMI reduction ...

Conference Call Information Rhythm Pharmaceuticals will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, July 9, to discuss these clinical data. Participants may register for the ...